Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

25.11 +0.91 (+3.74%)
Streaming Delayed Price Updated: 3:01 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in May Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth ↗
JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML. 
Via Benzinga
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
Syndax Announces Participation in March Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks ↗
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer ↗
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025. 
Via Benzinga
News headline image
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... 
Via Benzinga
News headline image
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
From Incyte and Syndax Pharmaceuticals
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Make Your Summer Unforgettable ↗
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace
News headline image
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.